摘要
目的 分析卡培他滨治疗胃癌术后辅助化疗的效果和安全性。方法 选取2014年1~12月收治的胃癌术后辅助化疗患者82例,治疗组患者采用卡培他滨辅助化疗,对照组联合使用卡培他滨和奥沙利铂化疗。结果 治疗组与对照组的中位生存期比较,差异无统计学意义（P〉0.05）。治疗组和对照组1年生存率和2年生存率比较,差异无统计学意义（P〉0.05）。治疗组和对照组不良反应发生率比较,差异具有统计学意义（P〈0.05）。结论 卡培他滨治疗胃癌术后辅助化疗临床效果显著。
Objective To analyze the efficacy and safety of capecitabine adjuvant chemotherapy in patients with gastric cancer after operation. MethodsFrom January to December 2014, 82 cases of patients gastric cancer after adjuvant chemotherapy, the treatment group patients was treated with capecitabine and chemotherapy, control group used in combination with capecitabine and oxaliplatin.Results The treatment group compared with the control group, the difference was not signiifcant （P〉 0.05）. The 1 year survival rate and 2 year survival rate of the treatment group and the control group were not significant （P〉0.05）. There was significant difference in incidence of adverse reactions between the treatment group and the control group （P〈0.05）.Conclusion The clinical effect of adjuvant chemotherapy on postoperative adjuvant chemotherapy in patients with gastric cancer.
出处
《中国继续医学教育》
2016年第25期135-136,共2页
China Continuing Medical Education
关键词
晚期胃癌
复发转移
卡培他滨
安全性
Advanced gastric cancer
Recurrence metastasis
Capecitabine
Security
